Market Assessment, Acute Coronary Syndrome Pharmacor G7 2015 Report

Last Updated 16 November 2015
Acute coronary syndrome (ACS)—an umbrella term that encompasses acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA)—is a leading cause of morbidity and mortality in the developed world. ACS is usually the outcome of atherosclerosis in the coronary arteries with concomitant endothelial dysfunction, followed by plaque disruption and thrombin formation. Despite ongoing improvements in ACS management, rates of reinfarction and death are high, and a pressing need remains for new antithrombotic and antiatherosclerotic therapies that can reduce ischemic complications and mortality in both the acute and the posthospital settings.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Acute Coronary Syndrome | Pharmacor | G7 | 2015

Related Market Assessment Reports

Acute Coronary Syndrome – Epidemiology – Epidemiology Dashboard

Acute Coronary Syndrome – Epidemiology – Extrapolated Worldwide Coverage

Acute Coronary Syndrome – Epidemiology – Mature Markets

Acute Coronary Syndrome – Epidemiology – Asia Pacific

Acute Coronary Syndrome – Epidemiology – Europe